Flutiform, an asthma medication developed by Britain-based Vectura Group, proved ineffective at treating chronic obstructive pulmonary disease in a recent late-stage trial, reported Reuters.
The double-blind trial included 1,767 patients in 16 countries. When compared to formoterol fumarate dihydrate — the conventional treatment of the disease — Flutiform did not significantly reduce the annual rate of worsening condition in patients with moderate to severe COPD.
"Whilst this result is disappointing, Flutiform continues to grow strongly based on the approved asthma indication, which continues to underpin our expectations for future growth of the product," said James Ward-Lilley, CEO of Vectura.
Flutiform reported $103.3 million in net sales for the past six months ending in June.
More articles on supply chain:
The rise of the unbranded drug ad: 5 things to know
FDA fast tracks experimental drug to treat Parkinson's
Roche's Zika test earns FDA emergency use authorization